Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Celcuity

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

IMCAS World Congress
Not Confirmed
arrow
arrow
IMCAS World Congress
Not Confirmed

GEDATOLISIB

NDC Package Code : 84577-750

Start Marketing Date : 2026-01-05

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

Looking for 1197160-78-3 / Gedatolisib API manufacturers, exporters & distributors?

Gedatolisib manufacturers, exporters & distributors 1

22

PharmaCompass offers a list of Gedatolisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gedatolisib manufacturer or Gedatolisib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gedatolisib manufacturer or Gedatolisib supplier.

PharmaCompass also assists you with knowing the Gedatolisib API Price utilized in the formulation of products. Gedatolisib API Price is not always fixed or binding as the Gedatolisib Price is obtained through a variety of data sources. The Gedatolisib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Gedatolisib

Synonyms

1197160-78-3, Pki-587, Pf-05212384, Pki 587, 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea, Pki587

Cas Number

1197160-78-3

Unique Ingredient Identifier (UNII)

96265TNH2R

About Gedatolisib

Gedatolisib is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, gedatolisib inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.

Gedatolisib Manufacturers

A Gedatolisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gedatolisib, including repackagers and relabelers. The FDA regulates Gedatolisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gedatolisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Gedatolisib Suppliers

A Gedatolisib supplier is an individual or a company that provides Gedatolisib active pharmaceutical ingredient (API) or Gedatolisib finished formulations upon request. The Gedatolisib suppliers may include Gedatolisib API manufacturers, exporters, distributors and traders.

click here to find a list of Gedatolisib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Gedatolisib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Gedatolisib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Gedatolisib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Gedatolisib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Gedatolisib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Gedatolisib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Gedatolisib suppliers with NDC on PharmaCompass.

Gedatolisib Manufacturers | Traders | Suppliers

Gedatolisib Manufacturers, Traders, Suppliers 1
85

We have 1 companies offering Gedatolisib

Get in contact with the supplier of your choice:

  1. Celcuity
Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.